Stealth BioTherapeutics said the FDA rejected its Barth syndrome drug elamipretide due to concerns over safety and efficacy. The company will resubmit its application, which could lead to accelerated approval.
Source: https://endpts.com/fda-rejects-stealths-rare-disease-drug-but-offers-potential-for-accelerated-approval